Patents Assigned to Genzyme Corporation
  • UDP glycosyltransferase inhibitors and methods of use
    Patent number: 11098056
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 24, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
  • SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210254063
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 19, 2021
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Methods and compositions for treating a Serpinc1-associated disorder
    Patent number: 11091759
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: August 17, 2021
    Assignee: Genzyme Corporation
    Inventors: Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
  • Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
    Publication number: 20210244720
    Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
    Type: Application
    Filed: January 19, 2021
    Publication date: August 12, 2021
    Applicant: Genzyme Corporation
    Inventors: Meehyung Cho, Timothy J. Turner, Erik Wallstroem
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 11083800
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Genzyme Corporation
    Inventors: Alejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
    Patent number: 11084864
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 10, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Methods for the quantitation of polypeptides
    Patent number: 11067584
    Abstract: Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: July 20, 2021
    Assignee: Genzyme Corporation
    Inventors: Christopher Morgan, Xiaokui Zhang
  • Perfusion culturing methods and uses thereof
    Patent number: 11060058
    Abstract: Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods. Also provided are multi-well cell culture plates, e.g., for use in perfusion culturing methods.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: July 13, 2021
    Assignee: Genzyme Corporation
    Inventors: Agata Villiger-Oberbek, Jianguo Yang, Yang Yang, Gabrielle Lorenzo
  • METHODS OF PROCESSING A FLUID INCLUDING A RECOMBINANT THERAPEUTIC PROTEIN AND USE THEREOF
    Publication number: 20210171572
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Applicant: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Inhibitors of T-cell activation
    Patent number: 11028170
    Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 8, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
  • Bone-Targeting Antibodies
    Publication number: 20210163584
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 3, 2021
    Applicant: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF
    Publication number: 20210162021
    Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 3, 2021
    Applicant: Genzyme Corporation
    Inventors: Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
    Publication number: 20210145941
    Abstract: The present invention provides compositions such as aqueous liquid compositions and lyophilized compositions comprising a recombinant human acid sphingomyelinase. Provided also are methods for using the compositions to treat patients who are deficient in acid sphingomyelinase.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Applicant: Genzyme Corporation
    Inventors: Mark Yang, Claudia Buser, Bernardo Perez-Ramirez, Grant Trierweiler, Sangeeta Benjwal
  • Glucosylceramide synthase inhibitors
    Patent number: 11008316
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: May 18, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Elyse Bourque, Mario A. Cabrera-Salazar, Cassandra Celatka, Seng H. Cheng, Bradford Hirth, Andrew Good, Katherine Jancsics, John Marshall, Markus Metz, Ronald K. Scheule, Renato Skerlj, Yibin Xiang, Zhong Zhao, John Leonard, Thomas Natoli, Elina Makino, Herve Husson, Oxana Beskrovnaya
  • Site-specific glycoengineering of targeting moieties
    Patent number: 10995148
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: May 4, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
  • AAV vectors for retinal and CNS gene therapy
    Patent number: 10982228
    Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.
    Type: Grant
    Filed: May 2, 2015
    Date of Patent: April 20, 2021
    Assignee: Genzyme Corporation
    Inventors: Abraham Scaria, Jennifer Sullivan
  • Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
    Patent number: 10973887
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 13, 2021
    Assignee: GENZYME CORPORATION
    Inventor: Yunxiang Zhu
  • Methods of processing a fluid including a recombinant therapeutic protein and use thereof
    Patent number: 10968252
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 6, 2021
    Assignee: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Method of preparing glucosylceramide synthase inhibitors
    Patent number: 10954230
    Abstract: This invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 23, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
  • DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
    Publication number: 20210077593
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: May 26, 2020
    Publication date: March 18, 2021
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, GENZYME CORPORATION
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray